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GUIDELINE
1. Introduction
Antenatal invasive obstetric procedures, which may be diagnostic 
or therapeutic, are performed at different stages of pregnancy for 
various indications. The commonest indication for an invasive 
procedure during pregnancy is for fetal karyotyping when a 
chromosomal abnormality or a genetic defect is suspected, either 
from the couple’s history or from ultrasound assessment of the 
fetus. Other less common but equally important indications may 
be diagnostic (fetoscopy, fetal tissue sampling, estimation of fetal 
haemoglobin) or therapeutic (aspiration of various fetal cavities, 
fetal blood transfusion and embryo reductions). 
In a high HIV prevalence setting like South Africa, where the 
estimated prevalence in antenatal clinic attendees was 30.2% in 
2010, a significant proportion of pregnant women in need of 
invasive procedures will be HIV infected.1 Clinicians need to be 
aware of the risk of mother-to-child transmission (MTCT) of HIV 
associated with invasive procedures, and also be aware of strategies 
available to minimise the risk. 
This information, together with the procedure-related risks of 
invasive testing, should be given to clients during the counselling 
session. Written informed consent relating to the procedure and the 
risk of MTCT should be obtained before the procedure. 
This guideline was developed to assist clinicians in counselling 
and managing HIV-infected pregnant women in need of invasive 
procedures. It is targeted at clinicians working in both the private 
and public sectors. For more detailed information on indications, 
techniques and risks associated with antenatal invasive procedures, 
the reader is referred to guidelines published elsewhere.2
2. Timing of invasive procedures in 
pregnancy  
Below is a list of commonly performed antenatal invasive obstetric 
procedures and the gestational ages at which each procedure can or 
should be performed:
•	 amniocentesis: from 16 weeks
•	 chorionic villus sampling: from 11 to 14 weeks
•	 cordocentesis: from 20 weeks
•	 fetoscopy: usually in the 2nd and 3rd trimesters
•	 fetal tissue sampling (biopsies of organs, muscle, etc.): usually in 
the 2nd and 3rd trimesters
•	 aspiration of various fetal cavities, shunt insertion: any 
gestational age – usually from 16 weeks
•	 embryo reductions: from 11 weeks.
3. Risk of MTCT with antenatal invasive 
procedures
There is limited literature on invasive obstetric procedures in the 
context of maternal HIV infection. Few studies have been published 
on the topic, most with a small number of participants. Important 
risk factors for MTCT such as maternal HIV viral load and CD4+ 
cell count are not always controlled for, and it may be difficult to 
infer causality in the reported cases of transmission after an invasive 
procedure. Without any maternal antiretroviral therapy initiated prior 
to an invasive procedure, the risk of MTCT is high, with rates of over 
30% reported in some studies.3,4 One study showed a fourfold increase 
in the risk of MTCT with third-trimester amniocentesis without 
any maternal antiretroviral cover.3  With the use of combination 
antiretroviral therapy prior to antenatal invasive procedures, the risk 
of MTCT is reportedly similar to that in an HIV-infected pregnant 
woman who has not had an invasive procedure.5-7 
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Despite the decrease in HIV transmission with antiretroviral cover, 
procedures such as chorionic villus sampling and cordocentesis 
should still be avoided in the HIV-infected woman as the risk of 
transmission to the fetus may be considerably higher. 
Guidelines on the techniques of performing invasive procedures 
should be adhered to, and where possible the transplacental route 
should be avoided owing to the higher risk of transmission.8
4. Recommendations on antiretroviral 
prophylaxis prior to invasive procedures
There is now general consensus in the literature that any HIV-
infected pregnant woman who needs to undergo an invasive 
obstetric procedure should have combination antiretroviral 
therapy initiated before the procedure, regardless of her CD4+ 
cell count.8,9 Ideally, antiretroviral therapy should be initiated 
at least 4 - 6 weeks before the procedure to achieve a significant 
level of maternal HIV viral suppression.10 If the gestational age 
precludes waiting for the period of 4 - 6 weeks, the clinician can 
still go ahead with the procedure as continuation of combination 
antiretroviral therapy after the procedure provides post-exposure 
prophylaxis. 
Studies and surveillance data on MTCT suggest a strong correlation 
between maternal HIV viral load at delivery and transmission 
to the fetus, with undetectable viral loads being associated with 
the lowest risk of transmission.11,12 There are no data available to 
demonstrate a viral load threshold below which HIV transmission 
is unlikely to occur following an antenatal invasive procedure. 
Results from general MTCT studies cannot be extrapolated to 
cases with invasive procedures. However, both the Royal College of 
Obstetricians and Gynaecologists and the British HIV Association 
recommend an undetectable maternal viral load at the time of the 
invasive procedure.8,9 If resources allow and there is sufficient time 
to wait prior to the invasive procedure, maternal viral load should be 
determined as part of the pre-procedure counselling.
HIV-infected women with an indication for an invasive procedure 
may present already on antiretroviral treatment (ART), initiated 
either before or after conception. They may also present on 
zidovudine (AZT) monotherapy initiated during pregnancy or on 
no antiretroviral therapy. All these scenarios will be considered, and 
recommendations on antiretroviral prophylaxis made.
4.1 ART initiated pre-conception (Table I)  
If a pregnant woman presents at a gestational age of less than 14 
weeks, and is on an efavirenz (EFV)-containing regimen, EFV should 
be switched to either nevirapine (NVP) or lopinavir/ritonavir (LPV/r). 
In the public sector, NVP is the first choice unless contraindicated.
There is no need to switch drugs if a pregnant woman is on an EFV-
containing regimen and presents at a gestational age of more than 14 
weeks, or is on a NVP- or a LPV/r-containing regimen. 
4.2 ART initiated post-conception
The rules above on ART initiated before conception also apply in 
pregnant women initiated on ART during pregnancy.
4.3 On no ART
Women not on ART can be classified by their CD4+ cell count level, 
and managed accordingly:
•	 CD4+ cell count ≤350 cells/µl 
•	 CD4+ cell count >350 cells/µl. 
4.3.1 CD4+ cell count ≤350 cells/µl, or WHO stage 3 or 4 
•	 Lifelong ART needs to be initiated as soon as possible. For the 
public sector, the choice of regimen is according to the South 
African National PMTCT guidelines (Table II).13
4.3.2 CD4+ cell count >350 cells/µl, and WHO stage 1 or 2 
•	 The pregnant woman needs to be initiated on combination ART 
before the invasive procedure. If AZT monotherapy has already 
been initiated, it must be stopped and combination therapy started.
Table I. Pre-conception ART regimen containing efavirenz (EFV)
Presentation before 14 weeks’ gestation Presentation after 14 weeks’ gestation
Switch from EFV to:
•		NVP	200	mg	12-hourly	OR
•		LPV/r	400/100	mg	12-hourly
Continue EFV 600 mg daily
Table II. Antenatal ART regimens for PMTCT, based on CD4+ cell count 
CD4 ≤350 cells/µl, or WHO stage 3 or 4 CD4 >350 cells/µl, and WHO stage 1 or 2
Lifelong ART initiation Prophylactic ART for invasive procedures
Combination of:
TDF 300 mg daily or AZT 300 mg 12-hourly
3TC 150 mg 12-hourly or FTC 200 mg daily
NVP 200 mg daily for 2 weeks then 200 mg 12-hourly
Combination of:
TDF 300 mg daily or AZT 300 mg 12-hourly
3TC 150 mg 12-hourly or FTC 200 mg daily
EFV 600 mg daily or LPV/r 400/100 mg 12-hourly
ART = antiretroviral therapy; AZT = zidovudine; EFV = efavirenz; FTC = emtricitabine; 3TC = lamivudine; LPV/r = lopinavir/ritonavir; NVP = nevirapine; TDF = tenofovir; WHO = World Health 
Organization. 
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•	 Given the higher risk of hepatotoxicity at this CD4+ cell count, 
our recommendation is to use either an EFV- or an LPV/r-
containing regimen with a nucleoside/nucleotide reverse 
transcriptase inhibitor (NRTI) backbone. The NRTI backbone 
can be a combination of tenofovir (TDF) and lamivudine (3TC), 
or emtricitabine (FTC), or AZT and 3TC (Table II). 
In all cases, combination ART should be continued until after 
delivery, and in cases where the mother elects to breastfeed, 
combination therapy must be continued until at least 1 week after 
breastfeeding cessation.
When stopping antiretrovirals, non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) need to be stopped a week prior to stopping 
NRTIs. This is done because NNRTIs have a longer half-life, and their 
earlier discontinuation confers a lower risk of NNRTI resistance.14
This guideline on invasive obstetric procedures in the HIV-infected 
pregnant woman is meant to be a guide for clinicians, to be used in 
counselling the woman/couple, and also in managing the woman 
who is eligible for an invasive procedure. Expert advice should be 
sought wherever necessary. 
As there are limited data on invasive obstetric procedures in HIV-
infected pregnant women, our recommendations are based on small 
observational studies and local experience. There is a need for more 
research on the topic to better inform practice. There is a particular 
need for information on the optimal duration of antiretroviral 
therapy and maternal viral load prior to the invasive procedure. 
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